Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure

Treatment options for patients with lower risk non-del(5q) myelodysplastic syndromes (MDS) who fail erythroid stimulating agents are restricted to one of the hypomethylating drugs with an expected response rate of ~50%. Ezatiostat HCl, an agent with the potential for producing multi-lineage response...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Quddus, Fahd, Clima, Jessica, Seedham, Helen, Sajjad, Ghulam, Galili, Naomi, Raza, Azra
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2010
Sujets:
Case Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2873355/
https://ncbi.nlm.nih.gov/pubmed/20416051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-3-16
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires